Rapalogix Health Expands Research Capabilities with New Laboratory at Princeton Innovation Center BioLabs
Rapalogix Health, a biotechnology company focused on developing longevity-based approaches to skin health, has announced the establishment of dedicated laboratory space at Princeton Innovation Center BioLabs in Princeton, New Jersey. The new facility represents an important expansion of the company’s internal scientific capabilities and will become the primary location for its translational research program focused on next-generation rapalogs.
Rapalogs are a proprietary class of compounds that form the scientific foundation of Rapalogix Health’s longevity-focused approach to skin care and its professional skincare brand, Re-Q Health. Through its newly established laboratory, the company plans to strengthen its ability to investigate the biological mechanisms associated with longevity pathways in skin, evaluate its growing portfolio of rapalog compounds, and advance new formulations and products supported by internally generated research.
The laboratory became operational on August 17, 2026, marking a significant step in Rapalogix Health’s efforts to build an internal research infrastructure capable of supporting the company’s long-term scientific and product development strategy.
Building an Internal Research Platform
The establishment of dedicated laboratory space is designed to give Rapalogix Health greater control over its translational research activities. Rather than relying exclusively on external research facilities, the company will now have an environment where its scientists can conduct experiments, evaluate hypotheses, analyze biological mechanisms, and move promising findings toward formulation development within a more integrated workflow.
The facility will serve as the central research site for studies involving Rapalogix Health’s rapalog portfolio. Scientists will use a combination of two-dimensional (2D), three-dimensional (3D), and more complex biological model systems to investigate longevity-related pathways and their potential relevance to skin biology.
These research activities are expected to encompass several areas, including the study of mechanisms of action, evaluation of individual compounds, investigation of formulation approaches, and generation of proprietary datasets that can inform future product development.
The company believes that maintaining research capabilities internally can help shorten the time between an initial scientific observation and its application in product development. Internal laboratory resources may also enable researchers to respond more quickly to emerging findings and refine experiments based on data generated during the research process.
Research Based on Longevity Biology
Rapalogix Health is developing its platform around the concept of applying longevity science to skin health. The company’s approach seeks to move beyond traditional anti-aging strategies by investigating biological pathways associated with cellular longevity, healthspan, and age-related changes in skin.
The company describes longevity science as a potential shift in the way skin aging is approached. Instead of focusing solely on visible signs of aging, such as wrinkles or changes in skin texture, Rapalogix Health is investigating biological mechanisms that may influence skin health over time.
Its research program is centered on rapalogs, the proprietary compound class that underpins the company’s Re-Q Health skincare platform. The company intends to use its new laboratory to better understand how these compounds interact with longevity-associated pathways in skin models and how those findings could potentially be translated into new skincare products.
This translational focus is intended to create a connection between laboratory-based discoveries and practical applications in professional skincare.
RLX-201 at the Center of the Research Program
A key component of Rapalogix Health’s research portfolio is RLX-201, the company’s proprietary longevity molecule. RLX-201 is the active compound featured in Re-Q Longevity Face Serum, making it an important element of the company’s current product and research strategy.
The new laboratory will provide an environment for researchers to further characterize RLX-201 and investigate its mechanisms of action. Researchers will also have the opportunity to compare the compound with other molecules in the company’s rapalog portfolio and evaluate different formulation approaches.
By conducting these investigations internally, Rapalogix Health aims to develop a deeper understanding of the biological properties of its compounds and generate proprietary evidence that can support future development decisions.
The company expects its research activities to extend beyond a single product, with the laboratory providing infrastructure for evaluating additional compounds, formulations, and potential applications as its pipeline develops.
Advanced Model Systems to Support Translational Research
The laboratory will incorporate multiple experimental model systems, including 2D and 3D models as well as complex biological systems. The use of different model types can allow researchers to examine biological activity from multiple perspectives and generate more comprehensive data during preclinical and translational research.
Two-dimensional models can provide controlled experimental environments for investigating specific cellular responses and molecular pathways. Three-dimensional systems, meanwhile, can offer additional structural and biological characteristics that may more closely represent aspects of tissue behavior.
Complex model systems can further support investigations into interactions among different biological components. By combining these approaches, Rapalogix Health intends to build a more detailed understanding of how its compounds may influence skin-related biology.
The company expects the data generated through these studies to contribute to its understanding of mechanisms of action and guide decisions around future product development.
Princeton Innovation Center BioLabs Provides Scientific Infrastructure
Rapalogix Health selected Princeton Innovation Center BioLabs as the location for its new research operations. The facility is a purpose-built life sciences incubator operated by BioLabs and founded by Princeton University.
The approximately 30,000-square-foot center provides fully equipped and licensed wet and dry laboratory space, shared scientific equipment, and on-site technical support. It also provides resident companies with access to a broader community that includes life science businesses, academic researchers, and industry partners.
For an emerging biotechnology company, access to an established laboratory environment can reduce the time and capital required to build a research facility from the ground up. Rapalogix Health can begin conducting experiments in an environment that already has scientific infrastructure and operational capabilities in place.
The company indicated that this arrangement allows it to direct a greater proportion of its resources toward scientific experimentation rather than laboratory construction and infrastructure development.
The location also provides access to a network of researchers and organizations operating within the broader life sciences ecosystem. This environment may create opportunities for scientific interaction, collaboration, and exchange of ideas as Rapalogix Health expands its research program.
Leadership Emphasizes Scientific Evidence
Rahul Mehta, PhD, CEO and Co-Founder of Rapalogix Health, described the establishment of the company’s laboratory as a deliberate step toward building a stronger scientific evidence base for longevity-focused skin health.
According to Mehta, internal research capabilities will allow the company to maintain greater control over the scientific questions it investigates while also improving the speed at which those questions can be addressed. The ability to generate data internally is expected to support a more direct connection between mechanistic research and formulation development.
Mehta also highlighted the value of Princeton Innovation Center BioLabs’ existing scientific infrastructure and community. By using a fully equipped laboratory environment, Rapalogix Health can concentrate resources on experiments and research programs rather than spending heavily on building and maintaining a standalone laboratory facility.
Manpreet Randhawa, PhD, Executive Director of Research and Development at Rapalogix Health, emphasized the broader scientific opportunity associated with longevity research.
Randhawa characterized longevity science as a significant shift from traditional approaches to anti-aging and said that access to equipped wet laboratories and a scientific community would allow the company to move more efficiently from hypotheses to experimental validation.
The company sees rigorous scientific investigation as an essential component of establishing longevity-focused skin health as a distinct category.
Supporting the Future of Re-Q Health
The new laboratory is also expected to support the continued development of Re-Q Health, Rapalogix Health’s professional skincare brand. The brand is built around the company’s proprietary rapalog technology and longevity-oriented scientific approach.
As research progresses, data generated at the Princeton facility could help inform future product formulations and provide scientific insights that guide the expansion of the Re-Q Health portfolio.
The company plans to investigate novel formulations alongside the biological properties of its compounds. This combination of scientific research and formulation development could help Rapalogix Health identify new ways to translate laboratory findings into products designed for professional skincare applications.
The internal research infrastructure may also allow the company to evaluate potential product concepts more efficiently as new scientific information becomes available.
A Foundation for Long-Term Innovation
The launch of the Princeton laboratory marks an important infrastructure milestone for Rapalogix Health as it seeks to establish longevity-based skin health as a differentiated area of biotechnology and skincare research.
With its own dedicated research space, the company can conduct translational studies, investigate mechanisms of action, explore new formulations, and build proprietary datasets around its rapalog platform. The facility is expected to play a central role in these activities as the company’s research portfolio develops.
The establishment of the laboratory also reflects the growing intersection between biotechnology and advanced skincare, where companies are increasingly investigating biological pathways associated with aging and tissue health rather than relying exclusively on conventional cosmetic approaches.
For Rapalogix Health, the new research facility provides a foundation for expanding its scientific program while supporting the development of future products based on its longevity platform. The combination of proprietary molecules such as RLX-201, advanced model systems, and dedicated laboratory capabilities is intended to strengthen the company’s ability to move from scientific discovery toward practical skincare applications.
With the facility operational since August 17, 2026, Rapalogix Health is now positioned to expand its internal translational research efforts and continue investigating the potential of next-generation rapalogs in skin biology. The company expects the new laboratory to become a central component of its long-term strategy as it works to generate the scientific evidence needed to advance longevity-focused approaches to skin health and develop the next generation of products under its Re-Q Health brand.
About Rapalogix Health
Rapalogix Health is a California-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products.
Re-Q Longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at dermatology and aesthetic practices in the United States. Re-Q Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.